• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Conclusions -This study based meta-analysis shows that it may be both safer and more effective to use NOACs as compared with VKA to treat patients with non-valvular AF and concomitant aspirin therapy. PMID: 29101289 [PubMed - as supplied by publisher]
Source: Circulation - November 3, 2017 Category: Cardiology Authors: Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, Brueckmann M, Kleine E, Ten Berg JM Tags: Circulation Source Type: research

Conscious Sedation versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights from the NCDR ® STS/ACC TVT Registry.
Conclusions -In U.S. practice, conscious sedation is associated with briefer length of stay and lower in-hospital and 30-day mortality compared to TAVR with general anesthesia in both unadjusted and adjusted analyses. These results suggest the safety of conscious sedation in this population, though comparative effectiveness analyses using observational data cannot definitively establish the superiority of one technique over another. PMID: 28864443 [PubMed - as supplied by publisher]
Source: Circulation - September 1, 2017 Category: Cardiology Authors: Hyman MC, Vemulapalli S, Szeto WY, Stebbins A, Patel PA, Matsouaka RA, Herrmann HC, Anwaruddin S, Kobayashi T, Desai ND, Vallabhajosyula P, McCarthy FH, Li R, Bavaria JE, Giri J Tags: Circulation Source Type: research

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared with Aspirin After TIA or Acute Ischemic Stroke in the SOCRATES Study.
Conclusions -Antiplatelet therapy with ticagrelor in patients with AIS or TIA showed a similar bleeding profile as aspirin for major bleeds. There were few ICrHs. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT01994720. PMID: 28655834 [PubMed - as supplied by publisher]
Source: Circulation - June 27, 2017 Category: Cardiology Authors: Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund Singh S, Denison H, Evans SR, Held P, Jahreskog M, Jonasson J, Mimematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, SOCRATES Steering Committee and Investigators Tags: Circulation Source Type: research

Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
CONCLUSIONS : In this secondary analysis of the MOMENTUM 3 trial, the HM3 LVAS demonstrated greater freedom from HRAEs in comparison with the HMII LVAS at 6 months. CLINICAL TRIAL REGISTRATION : URL: http://clinicaltrials.gov. Unique identifier: NCT02224755. PMID: 28385948 [PubMed - as supplied by publisher]
Source: Circulation - April 6, 2017 Category: Cardiology Authors: Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald GA, Tatooles AJ, Silvestry SC, John R, Caldeira C, Jeevanandam V, Boyle AJ, Sundareswaran KS, Sood P, Mehra MR Tags: Circulation Source Type: research

Correction to: Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.
Authors: PMID: 28193805 [PubMed - in process]
Source: Circulation - February 13, 2017 Category: Cardiology Tags: Circulation Source Type: research

SOURCE 3 Registry: Design and 30-Day Results of the European Post Approval Registry of the Latest Generation of the Sapien 3TM Transcatheter Heart Valve.
CONCLUSIONS: -Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when using this third generation TAVI device. PMID: 28104716 [PubMed - as supplied by publisher]
Source: Circulation - January 18, 2017 Category: Cardiology Authors: Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Ihlberg L, Neumann FJ, Tarantini G, Zamorano JL, Vahanian A Tags: Circulation Source Type: research

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.
CONCLUSIONS: -Low-dose aspirin did not affect the risk for cardiovascular events, but increased risk for gastrointestinal bleeding in patients with type 2 diabetes in a primary prevention setting. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00110448. PMID: 27881565 [PubMed - as supplied by publisher]
Source: Circulation - November 14, 2016 Category: Cardiology Authors: Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Morimoto T, JPAD Trial Investigators Tags: Circulation Source Type: research

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis.
CONCLUSIONS: -Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel. PMID: 27806998 [PubMed - as supplied by publisher]
Source: Circulation - November 1, 2016 Category: Cardiology Authors: Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang QW, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y Tags: Circulation Source Type: research

Wide Variation in Reported Rates of Stroke Across Cohorts of Patients with Atrial Fibrillation.
CONCLUSIONS: -There is substantial variation across cohorts in overall stroke rates and rates corresponding to CHA2DS2-VASc point scores. These variations can affect the point score threshold for recommending OAC in AF. The majority of cohorts did not observe stroke rates that would indicate a clear expected net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of 1 or 2. PMID: 27799272 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2016 Category: Cardiology Authors: Quinn GR, Severdija ON, Chang Y, Singer DE Tags: Circulation Source Type: research

Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
CONCLUSION: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary PCI strategy. The observed rates of major outcomes were similar, although with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT02808767. PMID: 27576777 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, Knot J, Jarkovsky J, Kala P, Rokyta R, Tousek F, Kramarikova P, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P Tags: Circulation Source Type: research

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
CONCLUSIONS: High-risk patients with prior myocardial infarction are at risk for stroke, approximately one-third of which are fatal or lead to moderate-to-severe disability. The addition of ticagrelor 60 mg twice daily significantly reduced this risk without an excess of hemorrhagic stroke but with more major bleeding. In high-risk patients with coronary disease, more intensive antiplatelet therapy should be considered not only to reduce the risk of coronary events, but also of stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01225562. PMID: 27576775 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu DY, Dalby AJ, Jensen EC, Held P, Morrow DA, Braunwald E, Sabatine MS Tags: Circulation Source Type: research

Long-Term Outcomes of the Ross Procedure versus Mechanical Aortic Valve Replacement: Propensity-Matched Cohort Study.
CONCLUSIONS: -Long-term survival and freedom from reintervention were comparable between the Ross procedure and mechanical AVR. However, the Ross procedure was associated with improved freedom from cardiac and valve-related mortality as well as a significant reduction in the incidence of stroke and major bleeding. In specialized centers, the Ross procedure represents an excellent option and should be considered for young and middle-aged adults undergoing AVR. PMID: 27496856 [PubMed - as supplied by publisher]
Source: Circulation - August 4, 2016 Category: Cardiology Authors: Mazine A, David TE, Rao V, Hickey E, Christie S, Manlhiot C, Ouzounian M Tags: Circulation Source Type: research

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients with Stable Ischemic Heart Disease and Prior Myocardial Infarction.
CONCLUSIONS: -Stratification of baseline atherothrombotic risk can assist with therapeutic decision-making regarding vorapaxar use for secondary prevention after MI. Clinical Trial Registration-http://www.clinicaltrials.gov; NCT00526474. PMID: 27440003 [PubMed - as supplied by publisher]
Source: Circulation - July 19, 2016 Category: Cardiology Authors: Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA Tags: Circulation Source Type: research

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
CONCLUSIONS: Among patients with on-treatment WRF, rivaroxaban was associated with lower rates of stroke and systemic embolism compared with warfarin, without an increase in the composite bleeding end point. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00403767. PMID: 27358435 [PubMed - in process]
Source: Circulation - July 2, 2016 Category: Cardiology Authors: Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR, ROCKET AF Steering Committee and Investigators Tags: Circulation Source Type: research

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Although there was an apparent decrease in relative efficacy to prevent arterial thromboembolism in the upper range of CrCl, the safety and net clinical benefit of HDER compared with warfarin are consistent across the range of renal function. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391. PMID: 27358434 [PubMed - in process]
Source: Circulation - July 2, 2016 Category: Cardiology Authors: Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E Tags: Circulation Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11